E-mail

E-mail a Wiley Online Library Link

Tahamtan Ahmadi, Elise A. Chong, Amanda Gordon, Nicole A. Aqui, Sunita D. Nasta, Jakub Svoboda, Anthony R. Mato and Stephen J. Schuster Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas Cancer 120

Version of Record online: 7 OCT 2013 | DOI: 10.1002/cncr.28405

The combination of lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant, indolent B-cell and mantle cell lymphomas. Overall response rate increased from 29% after two 28-day cycles of lenalidomide and low-dose dexamethasone to 58% after the addition of rituximab, suggesting that lenalidomide can overcome resistance to rituximab.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH